PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
26.85%
Revenue growth 1.25-1.5x CSIQ's 21.03%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
97.18%
Gross profit growth above 1.5x CSIQ's 15.38%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
13.62%
EBIT growth below 50% of CSIQ's 35.54%. Michael Burry would suspect deeper competitive or cost structure issues.
104.53%
Operating income growth above 1.5x CSIQ's 39.10%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
136.23%
Net income growth above 1.5x CSIQ's 16.13%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
136.36%
EPS growth above 1.5x CSIQ's 16.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
127.27%
Diluted EPS growth above 1.5x CSIQ's 16.67%. David Dodd would see if there's a robust moat protecting these shareholder gains.
6.93%
Slight or no buybacks while CSIQ is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
9.44%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
93.62%
OCF growth of 93.62% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
76.88%
FCF growth of 76.88% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-31.22%
Negative 10Y revenue/share CAGR while CSIQ stands at 116.22%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-55.30%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-46.50%
Negative 3Y CAGR while CSIQ stands at 32.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-101.54%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-101.62%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-100.43%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
253.98%
Net income/share CAGR at 50-75% of CSIQ's 359.74%. Martin Whitman might question if the firm’s product or cost base lags behind.
-96.52%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
101.80%
Below 50% of CSIQ's 590.91%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-99.54%
Negative equity/share CAGR over 10 years while CSIQ stands at 78.77%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-99.43%
Negative 5Y equity/share growth while CSIQ is at 79.17%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-99.08%
Negative 3Y equity/share growth while CSIQ is at 52.10%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.30%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-57.94%
Inventory is declining while CSIQ stands at 34.15%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
14.94%
Asset growth above 1.5x CSIQ's 3.01%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
112.55%
BV/share growth above 1.5x CSIQ's 4.46%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
1.93%
Debt growth far above CSIQ's 2.74%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
13.42%
We increase R&D while CSIQ cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
9.49%
SG&A growth well above CSIQ's 5.35%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.